Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.

Journal of hepatology - 1 Jul 2012

Hopkins Sam, DiMassimo Betty, Rusnak Pamela, Heuman Douglas, Lalezari Jacob, Sluder Ann, Scorneaux Bernard, Mosier Sarah, Kowalczyk Paul, Ribeill Yves, Baugh James, Gallay Philippe

Abstract excerpt

BACKGROUND & AIMS: SCY-635 is a non-immunosuppressive analog of cyclosporin A that inhibits cyclophilins A and B and hepatitis C virus (HCV) replication in vitro. In a phase 1b multi-dose escalation study, we evaluated the safety, plasma pharmacokinetics, and antiviral activity of 15 days of mono...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophilin A
Share to Cyclophilins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclosporins

Share to Interferon-alpha

Share to Interferon-beta

Share to Interferon-gamma

Share to Interferons

Share to Interleukins

Source

Identifiers

PMID: 22425702
DOI: 10.1016/j.jhep.2012.02.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22425702-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection.PMID 22425702Read ↗

The Cyclophilin Inhibitor SCY-635 Disrupts Hepatitis C Virus NS5A-Cyclophilin A ComplexesSemantic proximity Read ↗

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.Semantic proximity Read ↗

Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C InfectionSemantic proximity Read ↗

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.Semantic proximity Read ↗

Resistance to cyclosporin A derives from mutations in hepatitis C virus nonstructural proteins.Semantic proximity Read ↗

Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.Semantic proximity Read ↗

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including AlisporivirSemantic proximity Read ↗

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agentsSemantic proximity Read ↗

A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients.Semantic proximity Read ↗

Induction of antiviral gene expression by cyclosporine A, but not inhibition of cyclophilin A or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell lineSemantic proximity Read ↗

Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.Semantic proximity Read ↗

Identification of cellular and viral factors related to anti‐hepatitis C virus activity of cyclophilin inhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.